US Stock Movement: Oruka Therapeutics Plunges on September 24 Amid Safety Incident, Selling Pressure, and High-Level Correction

Oruka Therapeutics September 24 Major Drop Analysis

Keywords: security incident, selling pressure, high-level correction

1. On September 23, 2026, the company announced ORKA-001 week 28 data. While efficacy continued to improve, an 8% incidence of upper respiratory tract infection was reported, and two serious adverse events occurred; full 52-week data is still pending release in December. Long-term safety and durability of efficacy have yet to be fully validated.

2. On September 21, 2026, the company's general counsel sold 10 thousand shares, cashing out approximately $936,400; on September 23, 2026, Fairmount reportedly sold about 3.55 million shares, increasing the stock supply pressure.

3. As of August 28, 2026, the company's share price had risen about 65% over three months, with a cumulative increase of 175.32% year-to-date; on September 23, 2026, the biotech sector generally weakened, and early investors took profits after the release of clinical data, amplifying the share price correction.

(Disclaimer: This content is generated by AI summarizing publicly available information for reference only and does not constitute investment advice.)